Cargando…

Mitochondrial mutations drive prostate cancer aggression

Nuclear mutations are well known to drive tumor incidence, aggression and response to therapy. By contrast, the frequency and roles of mutations in the maternally inherited mitochondrial genome are poorly understood. Here we sequence the mitochondrial genomes of 384 localized prostate cancer patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, Julia F., Sabelnykova, Veronica Y., Weischenfeldt, Joachim, Simon, Ronald, Aguiar, Jennifer A., Alkallas, Rached, Heisler, Lawrence E., Zhang, Junyan, Watson, John D., Chua, Melvin L. K., Fraser, Michael, Favero, Francesco, Lawerenz, Chris, Plass, Christoph, Sauter, Guido, McPherson, John D., van der Kwast, Theodorus, Korbel, Jan, Schlomm, Thorsten, Bristow, Robert G., Boutros, Paul C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610241/
https://www.ncbi.nlm.nih.gov/pubmed/28939825
http://dx.doi.org/10.1038/s41467-017-00377-y
Descripción
Sumario:Nuclear mutations are well known to drive tumor incidence, aggression and response to therapy. By contrast, the frequency and roles of mutations in the maternally inherited mitochondrial genome are poorly understood. Here we sequence the mitochondrial genomes of 384 localized prostate cancer patients, and identify a median of one mitochondrial single-nucleotide variant (mtSNV) per patient. Some of these mtSNVs occur in recurrent mutational hotspots and associate with aggressive disease. Younger patients have fewer mtSNVs than those who diagnosed at an older age. We demonstrate strong links between mitochondrial and nuclear mutational profiles, with co-occurrence between specific mutations. For example, certain control region mtSNVs co-occur with gain of the MYC oncogene, and these mutations are jointly associated with patient survival. These data demonstrate frequent mitochondrial mutation in prostate cancer, and suggest interplay between nuclear and mitochondrial mutational profiles in prostate cancer.